View Older Stories View More Recent Stories

May 6, 2020 04:01PM G1 Therapeutics Provides First Quarter 2020 Corporate and Financial Update
Apr 29, 2020 07:00AM G1 Therapeutics to Provide First Quarter 2020 Corporate and Financial Update on May 6, 2020
Apr 7, 2020 07:00AM G1 Therapeutics to Present at 19th Annual Needham Virtual Healthcare Conference on April 14, 2020
Mar 12, 2020 08:10AM G1 Therapeutics (GTHX) Names Jack Bailey to Board
Mar 12, 2020 08:05AM G1 Therapeutics Announces Appointment of New Board Member and Chief Commercial Officer
Feb 26, 2020 04:01PM G1 Therapeutics Provides Fourth Quarter and Full-Year 2019 Corporate and Financial Update
Feb 24, 2020 07:00AM G1 Therapeutics to Present at Investor Conferences in March 2020
Feb 19, 2020 07:00AM G1 Therapeutics to Provide Fourth Quarter and Full Year 2019 Corporate and Financial Update on February 26, 2020
Feb 18, 2020 07:00AM G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020
Feb 17, 2020 07:00AM G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020
Feb 6, 2020 07:00AM G1 Therapeutics to Participate in Guggenheim Health Talks: Oncology Day on February 13, 2020
Feb 6, 2020 07:00AM G1 Therapeutics to Participate in Guggenheim Health Talks: Oncology Day on February 13, 2020
Jan 14, 2020 09:01AM Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer
Jan 14, 2020 07:00AM Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer
Jan 7, 2020 07:00AM G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
Dec 12, 2019 06:13AM G1 Therapeutics (GTHX) Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at SABCS
Dec 11, 2019 06:00PM G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)
Nov 26, 2019 07:00AM G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019
Nov 26, 2019 07:00AM G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019
Nov 12, 2019 07:00AM G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019
Nov 12, 2019 07:00AM G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019
Nov 5, 2019 04:00PM G1 Therapeutics Provides Third Quarter 2019 Corporate and Financial Update
Oct 29, 2019 07:00AM G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019
Oct 29, 2019 07:00AM G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019
Sep 29, 2019 06:00AM G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019
Sep 28, 2019 04:15AM G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant I
Sep 10, 2019 06:01AM G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress
Sep 3, 2019 07:00AM G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019
Sep 3, 2019 07:00AM G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019
Aug 7, 2019 04:01PM G1 Therapeutics Provides Second Quarter 2019 Corporate and Financial Update
Aug 6, 2019 07:00AM G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August
Aug 6, 2019 07:00AM G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August
Jul 31, 2019 07:00AM G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019
Jul 31, 2019 07:00AM G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019
Jul 30, 2019 07:01AM G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer
Jul 30, 2019 07:01AM G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer
Jun 18, 2019 06:04AM G1 Therapeutics (GTHX) Reports Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy
Jun 18, 2019 06:00AM G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic T
Jun 18, 2019 06:00AM G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic T
Jun 14, 2019 07:01AM G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019
Jun 14, 2019 07:01AM G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019
Jun 13, 2019 07:05AM G1 Therapeutics (GTHX) Names Board Member Garry Nicholson as Chairman, Succeeding Seth Rudnick M.D
Jun 13, 2019 07:01AM G1 Therapeutics Announces Updates to Board of Directors
Jun 13, 2019 07:01AM G1 Therapeutics Announces Updates to Board of Directors
Jun 11, 2019 07:00AM G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference
Jun 11, 2019 07:00AM G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference
Jun 3, 2019 05:50AM G1 Therapeutics (GTHX) Reports Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at ASCO 2019 Meetings
Jun 1, 2019 04:00PM G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 1, 2019 04:00PM G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2019 07:00AM G1 Therapeutics to Present Additional Trilaciclib Phase 2 Small Cell Lung Cancer Data at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
View More Recent Stories View Older Stories